Slingshot members are tracking this event:
Regeneron's (REGN) Evinacumab Designated Breakthrough Therapy for Hypercholesterolemia in Patients with Homozygous Familial Hypercholesterolemia (HoFH)
Slingshot Insights Explained
Apr 06, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Evinacumab, Breakthrough Therapy, Fda, Hypercholesterolemia, Homozygous Familial Hypercholesterolemia